首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
【24h】

Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

机译:改善门诊心脏病实践中心力衰竭的循证护理:注册表的主要结果是改善门诊环境中基于证据的心力衰竭疗法的使用(IMPROVE HF)。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: A treatment gap exists between heart failure (HF) guidelines and the clinical care of patients. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) prospectively tested a multidimensional practice-specific performance improvement intervention on the use of guideline-recommended therapies for HF in outpatient cardiology practices. METHODS AND RESULTS: Performance data were collected in a random sample of HF patients from 167 US outpatient cardiology practices at baseline, longitudinally after intervention at 12 and 24 months, and in single-point-in-time patient cohorts at 6 and 18 months. Participants included 34 810 patients with reduced left ventricular ejection fraction (< or =35%) and chronic HF or previous myocardial infarction. To quantify guideline adherence, 7 quality measures were assessed. Interventions included clinical decision support tools, structured improvement strategies, and chart audits with feedback. The performance improvement intervention resulted in significant improvements in 5 of 7 quality measures at the 24-month assessment compared with baseline: beta-blocker (92.2% versus 86.0%, +6.2%), aldosterone antagonist (60.3% versus 34.5%, +25.1%), cardiac resynchronization therapy (66.3% versus 37.2%, +29.9%), implantable cardioverter-defibrillator (77.5% versus 50.1%, +27.4%), and HF education (72.1% versus 59.5%, +12.6%) (each P<0.001). There were no statistically significant improvements in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use or anticoagulation for atrial fibrillation. Sensitivity analyses at the patient level and limited to patients with both baseline and 24-month quality measure data yielded similar results. Improvements in the single-point-in-time cohorts were smaller, and there were no concurrent control practices. CONCLUSIONS: The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting, a defined and scalable practice-specific performance improvement intervention, was associated with substantial improvements in the use of guideline-recommended therapies in eligible patients with HF in outpatient cardiology practices. CLINICAL TRIAL REGISTRATION:URL: http://www.clinicaltrials.gov. Unique identifier: NCT00303979.
机译:背景:心力衰竭(HF)指南与患者的临床护理之间存在治疗差距。改善门诊环境中基于证据的心力衰竭治疗方法的注册机构(IMPROVE HF)前瞻性地测试了针对门诊心脏病实践中针对心衰的指南推荐治疗的多维实践特定性能改善干预措施。方法和结果:在基线时,干预后12和24个月的纵向,以及在6点和18个月的单时间点患者队列中,从167名美国门诊心脏病实践的HF患者的随机样本中收集了性能数据。参与者包括34 810名左心室射血分数降低(<或= 35%),慢性心力衰竭或先前的心肌梗死的患者。为了量化准则遵守情况,评估了7种质量指标。干预措施包括临床决策支持工具,结构化的改善策略以及带有反馈的图表审计。与基线相比,性能改善干预措施在24个月评估中显着改善了7项质量指标中的5项:β受体阻滞剂(92.2%对86.0%,+ 6.2%),醛固酮拮抗剂(60.3%对34.5%,+ 25.1) %),心脏再同步治疗(66.3%比37.2%,+ 29.9%),植入式心脏除颤器(77.5%比50.1%,+ 27.4%)和HF教育(72.1%比59.5%,+ 12.6%)(每个P <0.001)。血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的使用或抗凝治疗房颤没有统计学上的显着改善。在患者级别进行的敏感性分析(仅限于具有基线和24个月质量测量数据的患者)得出了相似的结果。单时间点队列的改进较小,并且没有并行控制实践。结论:改善门诊环境中基于证据的心力衰竭治疗方法的注册管理机构是一项定义明确且可扩展的针对具体实践的绩效改善干预措施,与在符合条件的HF患者中使用指南推荐疗法的实质性改善相关。门诊心脏病实践。临床试验注册:URL:http://www.clinicaltrials.gov。唯一标识符:NCT00303979。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号